Vertex Adds To Myotonic Dystrophy Effort With Entrada Collaboration
Executive Summary
Entrada gets $250m cash and equity up front under four-year deal, which extends its runway and will enable it to focus on Duchenne muscular dystrophy. Vertex further diversifies its pipeline with a novel drug class.
You may also be interested in...
Deal Watch: Merck KGaA Teams Up With Mersana On STING Agonist ADCs
Mersana signs its third ADC partnership with big pharmas for the year with Merck agreement. Lilly expands its RNA editing partnership with ProQR, which now has the potential to earn an additional $2.5bn. Novartis continues its divestment efforts in deals with Harrow, Erasca.
Flush With CF Success, Vertex Prepares Next-Gen Pipeline For Busy 2023
Vertex’s dominance in cystic fibrosis looks secure for years to come, and 2023 and 2024 could see it bring more ground-breaking innovation to market.
Vertex/CRISPR Prepare To Take Exa-Cel To Regulators For SCD, TDT
The first gene-edited therapy will be submitted for sickle cell disease and transfusion-dependent beta thalassemia; it will compete with bluebird in both indications, but analysts anticipate blockbuster sales in excess of $2bn.